Star Equity (STRR) 10-Q 2 May 14 2014 Q1 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	3 Months Ended
	Mar. 31, 2014	Apr. 21, 2014
Document And Entity Information [Abstract]	'	'
Entity Registrant Name	'DIGIRAD CORP	'
Entity Central Index Key	'0000707388	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Non-accelerated Filer	'
Document Type	'10-Q	'
Document Period End Date	31-Mar-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q1	'
Amendment Flag	'false	'
Entity Common Stock, Shares Outstanding	'	18,504,279

Condensed_Consolidated_Stateme

Condensed Consolidated Statements Of Comprehensive Income (Loss) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Revenues:	'	'
Diagnostic Services	$9,555	$8,939
Diagnostic Imaging	3,442	2,607
Total revenues	12,997	11,546
Cost of revenues:	'	'
Diagnostic Services	7,534	6,825
Diagnostic Imaging	2,021	1,904
Total cost of revenues	9,555	8,729
Gross profit	3,442	2,817
Operating expenses:	'	'
Research and development	0	818
Marketing and sales	1,095	1,236
General and administrative	1,995	2,102
Amortization of intangible assets	66	66
Restructuring charges	441	1,004
Total operating expenses	3,597	5,226
Loss from operations	-155	-2,409
Other income (expense):	'	'
Interest and other income, net	17	22
Interest expense	-8	0
Total other income	9	22
Loss before income taxes	-146	-2,387
Income tax expense	-2	-32
Net loss	-148	-2,419
Net loss per share - Basic and diluted	($0.01)	($0.13)
Weighted average shares outstanding – basic and diluted	18,518	19,322
Dividends declared per common share	$0.05	$0
Other comprehensive loss:	'	'
Unrealized loss on marketable securities	-18	-40
Total other comprehensive loss	-18	-40
Comprehensive loss	($166)	($2,459)

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$9,549	$18,744
Securities available-for-sale	9,871	7,673
Accounts receivable, net	7,308	5,430
Inventories, net	3,755	3,881
Other current assets	697	697
Restricted cash	477	244
Total current assets	31,657	36,669
Property and equipment, net	4,514	4,153
Intangible assets, net	2,867	353
Goodwill	1,459	184
Other assets	62	92
Total assets	40,559	41,451
Liabilities and stockholders' equity	'	'
Accounts payable	1,293	611
Accrued compensation	2,622	3,472
Accrued warranty	148	137
Deferred revenue	1,381	1,631
Other accrued liabilities	2,103	1,774
Total current liabilities	7,547	7,625
Other liabilities	667	440
Total liabilities	8,214	8,065
Commitments and contingencies (Note 9)	'	'
Stockholders' equity:	'	'
Preferred stock, $0.0001 par value: 10,000,000 shares authorized; no shares issued or outstanding	0	0
Common stock, $0.0001 par value: 80,000,000 shares authorized; 18,504,279 shares issued and outstanding (net of treasury shares) at March 31, 2014 and December 31, 2013	2	2
Treasury stock, at cost; 2,588,484 shares at March 31, 2014 and December 31, 2013	-5,728	-5,728
Additional paid-in capital	156,093	156,968
Accumulated other comprehensive loss	-20	-2
Accumulated deficit	-118,002	-117,854
Total stockholders’ equity	32,345	33,386
Total liabilities and stockholders’ equity	$40,559	$41,451

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Statement of Financial Position [Abstract]	'	'
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	80,000,000	80,000,000
Common stock, shares issued	18,504,279	18,504,279
Common stock, shares outstanding	18,504,279	18,504,279
Treasury stock, shares	2,558,484	2,588,484

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements Of Cash Flows (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Operating activities	'	'
Net loss	($148)	($2,419)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation	387	427
Amortization of intangible assets	66	66
Provision for bad debt	21	11
Stock-based compensation	50	121
Gain on sale of assets	5	0
Amortization of premiums on investments	51	46
Changes in operating assets and liabilities:	'	'
Accounts receivable	-1,699	500
Inventories	293	130
Other assets	70	-89
Accounts payable	449	352
Accrued compensation	-1,019	252
Deferred revenue	-250	-369
Other liabilities	168	-197
Restricted cash	-233	0
Net cash used in operating activities	-1,789	-1,169
Investing activities	'	'
Purchases of property and equipment	-571	-189
Purchases of securities available-for-sale	-2,617	-4,679
Sales and maturities of securities available-for-sale	350	2,050
Net cash paid for acquisition	-3,470	0
Net cash used in investing activities	-6,308	-2,818
Financing activities	'	'
Issuances of common stock	0	29
Repurchases of common stock	0	-20
Dividend paid	-925	'
Repayment of long-term debt	-131	'
Repayment of obligations under capital leases	42	0
Net cash provided by (used in) financing activities	-1,098	9
Net decrease in cash and cash equivalents	-9,195	-3,978
Cash and cash equivalents at beginning of period	18,744	19,514
Cash and cash equivalents at end of period	$9,549	$15,536

The_Company

The Company	3 Months Ended
	Mar. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
The Company	'
	The Company
	Digirad Corporation (“Digirad”), a Delaware corporation, is one of the largest national providers of in-office nuclear cardiology imaging and ultrasound imaging services, and also provides cardiac event monitoring services. These services are provided to physician practices, hospitals and imaging centers through our Diagnostic Services reportable segment. Digirad also sells medical diagnostic imaging systems, including solid-state gamma cameras, for nuclear cardiology and general nuclear medicine applications, as well as provides service on the products sold, through our Diagnostic Imaging reportable segment. These two reportable segments, Diagnostic Services and Diagnostic Imaging, are collectively referred to herein as the “Company.”
	The accompanying condensed consolidated financial statements include the operations of both segments. Intercompany accounts and transactions are accounted for at cost and have been eliminated in consolidation. All our long-lived assets are located in the United States and substantially all of our revenues arise from sales activity in the United States.
	Basis of Presentation
	The unaudited condensed consolidated financial statements included in this Form 10-Q have been prepared in accordance with the U.S. Securities and Exchange Commission (“SEC”) instructions for Quarterly Reports on Form 10-Q. Accordingly, the condensed consolidated financial statements are unaudited and do not contain all the information required by U.S. generally accepted accounting principles (“GAAP”) to be included in a full set of financial statements. The unaudited condensed consolidated balance sheet at December 31, 2013 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by GAAP for a complete set of financial statements. The audited consolidated financial statements for our fiscal year ended December 31, 2013, filed with the SEC on Form 10-K on March 20, 2014 include a summary of our significant accounting policies and should be read in conjunction with this Form 10-Q. In the opinion of management, all material adjustments necessary to present fairly the results of operations, cash flows and balance sheets for such periods have been included in this Form 10-Q. All such adjustments are of a normal recurring nature. In addition certain reclassifications have been made to the prior period financial statements to conform to the current period presentation. The results of operations for interim periods are not necessarily indicative of the results of operations for the entire year.
	Preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses. By their nature, estimates are subject to an inherent degree of uncertainty. Actual results could differ from management’s estimates.
	The financial results for the three months ended March 31, 2014 include the financial results of Telerhythmics, LLC for the period since the acquisition date of March 13, 2014. See Note 3 for more information related to the acquisition of Telerhythmics, LLC.

Basic_And_Diluted_Net_Loss_Per

Basic And Diluted Net Loss Per Share	3 Months Ended
	Mar. 31, 2014
Earnings Per Share, Basic and Diluted [Abstract]	'
Basic and Diluted Net Income (Loss) Per Share	'
	Basic and Diluted Net Loss Per Share
	For the three months ended March 31, 2014 and 2013, basic net loss per common share is computed by dividing net loss by the weighted average number of common shares and vested restricted stock units outstanding during the period. Diluted net loss per common share is calculated to give effect of all dilutive securities, if applicable, using the treasury stock method.
	The following table sets forth the reconciliation of shares used to compute basic and diluted net loss per share for the periods indicated:
		Three Months Ended March 31,
	(shares in thousands)	2014	2013
	Weighted average shares outstanding - basic	18,518	19,322
	Dilutive potential common stock outstanding:
	Stock options	—	—
	Restricted stock units	—	—
	Weighted average shares outstanding - diluted	18,518	19,322
	The following weighted average outstanding common stock equivalents were not included in the calculation of diluted net loss per share because their effect was anti-dilutive:
		Three Months Ended March 31,
	(shares in thousands)	2014	2013
	Stock options	373	303
	Restricted stock units	—	16
	Total	373	319

Acquisition_of_Telerhythmics_N

Acquisition of Telerhythmics (Notes)	3 Months Ended
	Mar. 31, 2014
Business Combinations [Abstract]	'
Acquisition of Telerhythmics, LLC	'
	Acquisition of Telerhythmics, LLC
	On March 13, 2014, we entered into a membership interest purchase agreement (the “Purchase Agreement”) to acquire 100% of the membership interest of Telerhythmics, LLC ("Telerhythmics"), a provider of 24 hour cardiac monitoring services. Telerhythmics and Digirad each have a very similar customer base, yet with only minor overlaps in current customers. We believe this similar customer base will allow us to leverage each company’s strengths to grow sales and also diversify Digirad service offerings.
	Under the terms of the Purchase Agreement, we paid to the sellers of the membership interest (the "Sellers") aggregate estimated up front consideration of $3.52 million and assumed approximately $131,000 in debt. In addition, there is an aggregate earn-out opportunity of up to $501,000 from the period March 14, 2014 through December 31, 2016 based on the Telerhythmics business meeting certain earnings before interest, taxes, depreciation and amortization (“EBITDA”) milestones. The Sellers will receive fifty percent (50%) of the EBITDA generated by the Telerhythmics business in excess of the EBITDA milestone amounts, which are as follows:
	•	$415,000 of EBITDA for the period from the closing date through December 31, 2014,
	•	$825,000 of EBITDA for the period from January 1, 2015 through December 31, 2015; and
	•	$825,000 of EBITDA for the period from January 1, 2016 through December 31, 2016.
	At March 31, 2014, we have estimated the fair value of the contingent earn-out opportunity to be $220,000. The earn-out opportunity is estimated based on expected performance of the business over the period from the acquisition date through December 31, 2016, utilizing an income approach. It is reasonably possible that our estimate of the earn-out potential could change in the near term. Any adjustment in the estimated earn-out opportunity until settled will be recorded as a gain or loss to current operations in the period the estimate changes.
	The Purchase Agreement is also subject to a post-closing purchase price adjustment based on the final working capital balance, as defined in the Purchase Agreement.
	The following table summarizes the purchase price allocation recognized as of the close date of March 13, 2014:
			13-Mar-14
	Assets
	Current assets:
	Accounts receivable, net		$	200
	Other current assets		41
	Total current assets		241
	Property and equipment, net		290
	Intangible assets, net		2,580
	Goodwill		1,275
	Total assets		$	4,386
	Accounts payable		$	36
	Accrued compensation		169
	Other accrued liabilities		356
	Current portion of long-term debt		131
	Total current liabilities		692
	Other liabilities		174
	Total liabilities		$	866
	The long-term debt was subsequently paid in full on March 28, 2014.
	The goodwill recognized as part of the transaction primarily represents synergies between Digirad and Telerhythmics that were not separately identified as part of the acquisition valuation process. Telerhythmics activities are considered their own operating segment, which is aggregated into our Diagnostic Services reportable segment (formerly Digirad Imaging Solutions). The resulting goodwill from the acquisition is expected to be deductible for Federal and state tax reporting purposes.
	As of March 31, 2014, the final working capital adjustment has not been completed, and therefore the accounting for the acquisition is incomplete. We have estimated the working capital adjustment at March 13, 2014 at approximately $49,000 due to the Sellers, which is included in the estimated consideration above. It is reasonably possible this estimated working capital adjustment could change based on the final agreed upon amount pursuant to the Purchase Agreement. Any adjustment to this amount will affect the purchase consideration, and therefore the allocation of the purchase price, with the majority of any such adjustment likely affecting the recorded goodwill amount. We anticipate closing the measurement period by June 30, 2014.
	The below tables display estimated proforma results had the business acquisition been completed as of January 1, 2013. In deriving the proforma results, we utilized the historical operating results of Telerhythmics and adjusted for the impact of the purchase accounting and transaction costs as if the acquisition occurred on January 1, 2013.
			Three Months Ended March 31, 2014							Three Months Ended March 31, 2013
			Digirad			Telerhythmics		Proforma		Digirad			Telerhythmics			Proforma
	Revenues		$	12,742		$	1,410	$	14,152	$	11,546		$	1,413		$	12,959
	Net income (loss)		$	19		$	7	$	26	$	(2,419	)	$	(115	)	$	(2,534	)
	Included within our consolidated operating results for the period ending March 31, 2014 are Telerhythmics operations for the period March 14, 2014 through March 31, 2014 as follows:
			March 14, 2014 - March 31, 2014
	Revenues		$	255
	Net loss		$	(167	)
	Included within the results for Telerhythmics is approximately $155,000 of transaction costs related to the acquisition. These costs are classified as general and administrative expenses in the consolidated statements of comprehensive loss.

Inventories

Inventories	3 Months Ended
	Mar. 31, 2014
Inventory Disclosure [Abstract]	'
Inventories	'
	Inventories
	Our inventories are stated at the lower of cost (first-in, first-out) or market (net realizable value) and we review inventory balances for excess and obsolete inventory levels on a quarterly basis.
	(in thousands)	March 31,			December 31,
		2014			2013
	Raw materials	$	2,407		$	2,619
	Work-in-process	3,048			3,189
	Finished goods	669			616
		6,124			6,424
	Less reserve for excess and obsolete inventories	(2,369		)	(2,543		)
	Inventories, net	$	3,755		$	3,881

Property_and_Equipment_Notes

Property and Equipment (Notes)	3 Months Ended
	Mar. 31, 2014
Property and Equipment [Abstract]	'
Property and Equipment	'
	Property and Equipment
	(in thousands)	March 31,			December 31,
		2014			2013
	Machinery and equipment	$	23,216		$	22,596
	Computer hardware and software	2,520			2,497
	Leasehold improvements	900			861
		26,636			25,954
	Accumulated depreciation	(22,122		)	(21,801		)
	Property and equipment, net	$	4,514		$	4,153

Intangibles_and_Goodwill_Notes

Intangibles and Goodwill (Notes)	3 Months Ended
	Mar. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Intangibles and Goodwill	'
			31-Mar-14
			Weighted Average Useful Life (years)	Gross Carrying Amount		Accumulated Amortization			Intangible Assets, Net (1)
	Intangible assets with infinite useful lives:
	Goodwill (2)		Indefinite	$	1,459	$	—		$	1,459
	Intangible assets with finite useful lives:
	Customer relationships (2)		8.3	$	4,850	$	(2,682	)	$	2,168
	Trademarks (2)		9	600		(3		)	597
	Patents		4.8	141		(108		)	33
	Covenants not to compete (2)		5	70		(1		)	69
	Total intangible assets, net			$	5,661	$	(2,794	)	$	2,867
			31-Dec-13
			Weighted Average Useful Life (years)	Gross Carrying Amount		Accumulated Amortization			Intangible Assets, Net
	Intangible assets with infinite useful lives:
	Goodwill		Indefinite	$	184	$	—		$	184
	Intangible assets with finite useful lives:
	Customer relationships		3.5	$	2,940	$	(2,622	)	$	318
	Patents		4.9	141		(106		)	35
	Total intangible assets, net			$	3,081	$	(2,728	)	$	353
	-1	Amortization expense for intangible assets, net was $0.1 million for the three months ended March 31, 2014 and 2013. Estimated amortization expense for intangible assets for the remainder of 2014 is $0.3 million, for 2015 is $0.4 million, for 2016 is $0.4 million, for 2017 is $0.4 million, for 2018 is $0.3 million, for 2019 and thereafter is $1.2 million.
	-2	As a result of our acquisition of Telerhythmics, LLC on March 13, 2014, we recored certain intangible assets. See Note 3.

Restructuring_Charges

Restructuring Charges	3 Months Ended
	Mar. 31, 2014
Restructuring and Related Activities [Abstract]	'
Restructuring Charges	'
	Restructuring Charges
	Diagnostic Imaging restructuring initiative
	On February 28, 2013, we announced a plan to restructure our Diagnostic Imaging business to significantly reduce costs and focus on maximizing cash flow from our Diagnostic Services business (the "Diagnostic Imaging restructuring initiative"). The Diagnostic Imaging restructuring initiative included a reduction in force. In addition, as part of the Diagnostic Imaging restructuring initiative, we entered into an agreement in September 2013 with a third party to outsource the majority of the manufacturing associated with our cameras. As a result of the Diagnostic Imaging restructuring initiative, we incurred a total of $1.8 million in restructuring charges, the majority of which were incurred during fiscal year 2013. Included in the total Diagnostic Imaging restructuring initiative charges are $1.6 million of employee related costs, with the remaining costs consisting of contract termination costs and other related costs. All restructuring efforts associated with this initiative were substantially complete as of March 31, 2014.
	The following table includes information regarding our Diagnostic Imaging restructuring initiative:
	(in thousands)	Accrued at December 31, 2013		Accrued Costs		Cash Payments and Other Reductions		Accrued at March 31, 2014
	Total Diagnostic Imaging restructuring initiative	$	489	$	27	$	396	$	120
	All accrued Diagnostic Imaging restructuring charges at March 31, 2014 are included in the accrued compensation line item in the unaudited condensed consolidated balance sheets. All the Diagnostic Imaging restructuring charges are included in the Diagnostic Imaging segment.
	Facilities restructuring initiative
	On January 27, 2014, we announced a plan to exit our 47,000 square foot former headquarters facility in Poway, California (the "Facilities restructuring initiative"). This action was undertaken as the facility has excess space and capacity given our current operating plan. We entered into a termination agreement to end the lease on the facility as of April 30, 2014. The original term of the lease would have continued through February 29, 2016. Concurrently with the termination of the lease for the 47,000 square foot Poway, California facility, we entered into a new lease agreement on January 23, 2014 for a separate 21,300 square foot facility in Poway, California to house our Diagnostic Imaging operations.
	As a result of the Facilities restructuring initiative, we estimate that we will incur in total approximately $0.5 million to $0.7 million in restructuring charges, which we anticipate to be incurred in the first three quarters of fiscal year 2014. The estimated charges are comprised of lease termination, moving and other related costs. Through March 31, 2014, we have incurred approximately $0.4 million of charges associated with the Facilities restructuring initiative, consisting primarily of lease termination costs. Restructuring liabilities and associated charges are measured at fair value as incurred.
	The following table includes information regarding our Facilities restructuring initiative:
	(in thousands)	Accrued at December 31, 2013		Accrued Costs		Cash Payments and Other Reductions		Accrued at March 31, 2014
	Total Facilities restructuring initiative	$	—	$	414	$	256	$	158
	All accrued Facilities restructuring charges at March 31, 2014 are included in the other accrued liabilities line item in the unaudited condensed consolidated balance sheets. All the Facilities restructuring charges for the period ended March 31, 2014 are included in the Diagnostic Imaging segment.

Financial_Instruments

Financial Instruments	3 Months Ended
	Mar. 31, 2014
Fair Value Disclosures [Abstract]	'
Financial Instruments	'
	Financial Instruments
	Assets and Liabilities Measured at Fair Value on a Recurring Basis. The following table presents information about our financial assets and liabilities that are measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation techniques we utilize to determine such fair value at March 31, 2014 and December 31, 2013.
		Fair Value as of March 31, 2014
	(in thousands)	Level 1				Level 2				Level 3				Total
	Assets:
	Corporate debt securities	$	—			$	9,871			$	—			$	9,871
	Liabilities:
	Acquisition related contingent consideration	$	—			$	—			$	220			$	220
		Fair Value as of December 31, 2013
	(in thousands)	Level 1				Level 2				Level 3				Total
	Assets:
	Corporate debt securities	$	—			$	7,673			$	—			$	7,673
	The fair value of our corporate debt securities is determined using proprietary valuation models and analytical tools. These valuation models and analytical tools use market pricing or prices for similar instruments that are both objective and publicly available, including matrix pricing or reported trades, benchmark yields, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids and/or offers. We did not reclassify any investments between levels in the fair value hierarchy during the three months ended March 31, 2014.
	The acquisition related contingent consideration is related to our acquisition of Telerhythmics on March 13, 2014 (See Note 3).  We will reassess the fair value of the contingent consideration to be settled in cash related to our acquisition of Telerhythmics on a quarterly basis using the income approach, which is a Level 3 measurement. Significant assumptions used in the measurement include probabilities of achieving the EBITDA milestones.
	Securities Available for Sale
	Securities available-for-sale primarily consist of investment grade corporate debt securities. We classify all securities as available-for-sale and as current assets, as the sale of such securities may be required prior to maturity to execute management strategies. These securities are carried at fair value, with the unrealized gains and losses reported as a component of accumulated other comprehensive income (loss) in stockholders' equity until realized. Realized gains and losses from the sale of available-for-sale securities, if any, are determined on a specific identification basis. A decline in the market value of any available-for-sale security below cost that is determined to be other than temporary will result in an impairment charge to earnings and a new cost basis for the security is established. No such impairment charges were recorded for any period presented. It is not more likely than not that we will be required to sell investments before recovery of their amortized costs. Premiums and discounts are amortized or accreted over the life of the related security as an adjustment to yield using the straight-line method and included in interest income. Interest income is recognized when earned. Realized gains and losses on investments in securities are included in other income (expense) within the condensed consolidated statements of comprehensive income (loss). The realized gains and losses on these sales were minimal for the three months ended March 31, 2014 and 2013.
	The following table sets forth the composition of securities available-for-sale as of March 31, 2014 and December 31, 2013.
		Maturity in		Amortized Cost				Unrealized								Fair Value
	As of March 31, 2014 (in thousands)	Years						Gains				Losses
	Corporate debt securities	3 or less		$	9,891			$	6			$	(26	)		$	9,871
		Maturity in		Amortized Cost				Unrealized								Fair Value
	As of December 31, 2013 (in thousands)	Years						Gains				Losses
	Corporate debt securities	3 or less		$	7,675			$	—			$	(2	)		$	7,673

Commitments_And_Contingencies

Commitments And Contingencies	3 Months Ended
	Mar. 31, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	Commitments and Contingencies
	Leases
	We currently lease facilities and certain automotive equipment under non-cancelable operating leases expiring from April 1, 2014 through February 28, 2021. Rent expense is recognized on a straight-line basis over the initial lease term and those renewal periods that are reasonably assured as determined at lease inception. The difference between rent expense and rent paid is recorded as deferred rent and is included in other liabilities. Rent expense was approximately $0.4 million for the three months ended March 31, 2014 and 2013.
	As of March 31, 2014, we financed certain information technology and medical equipment and vehicles under capital leases. These obligations are secured by the specific equipment financed under each lease and will be repaid monthly over the remaining lease terms through March 31, 2018.
	The future minimum lease payments due under both non-cancelable operating leases and capital leases having initial or remaining lease terms in excess of one year as of March 31, 2014 are as follows (in thousands):
		Operating		Capital
		Leases		Leases
	2014	$	662	$	161
	2015	883		214
	2016	522		140
	2017	258		24
	2018	215		3
	2019	221		—
	Thereafter	266		—
	Total minimum lease payments	$	3,027	$	542
	Other matters. In the normal course of business, we have been, and will likely continue to be, subject to litigation or administrative proceedings incidental to our business, such as claims related to customer disputes, employment practices, wage and hour disputes, product liability, professional liability, commercial disputes, licensure restrictions or denials, and warranty or patent infringement. Responding to litigation or administrative proceedings, regardless of whether they have merit, can be expensive and disruptive to normal business operations. We are not able to predict the timing or outcome of these matters.

Income_Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2014
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	Income Taxes
	As of December 31, 2013, we had unrecognized tax benefits of approximately $1.6 million. Included in the unrecognized tax benefits were $1.3 million of tax benefits that, if recognized, would have a favorable impact on our annual effective tax rate, subject to the valuation allowance. We do not expect our unrecognized tax benefits to change significantly over the next 12 months.
	We file income tax returns in the U.S. and in various state jurisdictions with varying statutes of limitations. We are no longer subject to income tax examination by tax authorities for years prior to 2008; however, our net operating loss and research credit carry-forwards arising prior to that year are subject to adjustment. It is our policy to recognize interest expense and penalties related to income tax matters as a component of income tax expense.

Segments

Segments	3 Months Ended
	Mar. 31, 2014
Segment Reporting [Abstract]	'
Segments	'
	Segments
	Our reportable segments have been determined based on the nature of the products and/or services offered to customers or the nature of their function in the organization. We evaluate performance based on the operating income (loss) contributed by each segment.
	On March 13, 2014, we acquired all the outstanding membership interest of Telerhythmics, LLC (See Note 3). As part of the acquisition, we evaluated Telerhythmics' business operations, both on a quantitative and qualitative basis, and determined its business operations appropriately met the criteria to be aggregated with our Diagnostic Services business in accordance with the authoritative accounting guidance for segment reporting. The Diagnostic Services reportable segment was renamed in conjunction with the acquisition from Digirad Imaging Solutions.
	The financial results below for the three months ended March 31, 2014 include the financial results of Telerhythmics, LLC for the period since the acquisition date of March 13, 2014.
		Three Months Ended March 31,
	(in thousands)	2014			2013
	Gross profit by segment:
	Diagnostic Services	$	2,021		$	2,114
	Diagnostic Imaging	1,421			703
	Condensed consolidated gross profit	$	3,442		$	2,817
	Income (loss) from operations by segment:
	Diagnostic Services	$	(333	)	$	(144	)
	Diagnostic Imaging (1)	178			(2,265		)
	Condensed consolidated loss from operations	$	(155	)	$	(2,409	)
	Depreciation and amortization:
	Diagnostic Services	$	375		$	392
	Diagnostic Imaging	78			101
	Condensed consolidated depreciation and amortization	$	453		$	493
	(in thousands)	As of March 31, 2014			As of December 31, 2013
	Identifiable assets by segment:
	Diagnostic Services	$	15,172		$	11,874
	Diagnostic Imaging	25,387			29,577
	Condensed Consolidated assets	$	40,559		$	41,451
	(1) Included in the Diagnostic Imaging income (loss) from operations for the three months ended March 31, 2014 and 2013, are approximately $0.4 million and $1.0 million of charges, respectively, associated with our Diagnostic Imaging restructuring initiative (See Note 7).

Subsequent_Event_Notes

Subsequent Event (Notes)	3 Months Ended
	Mar. 31, 2014
Subsequent Events [Abstract]	'
Subsequent Event	'
	Subsequent Events
	On May 1, 2014, the Company’s Board of Directors declared a cash dividend of $0.05 per share payable on May 27, 2014 to shareholders of record on May 13, 2014.

Financial_Instruments_policies

Financial Instruments (policies)	3 Months Ended
	Mar. 31, 2014
Fair Value Disclosures [Abstract]	'
Fair Value of Financial Instruments, Policy	'
	The fair value of our corporate debt securities is determined using proprietary valuation models and analytical tools. These valuation models and analytical tools use market pricing or prices for similar instruments that are both objective and publicly available, including matrix pricing or reported trades, benchmark yields, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids and/or offers.
Securities Available-for-sale, Policy	'
	Securities Available for Sale
	Securities available-for-sale primarily consist of investment grade corporate debt securities. We classify all securities as available-for-sale and as current assets, as the sale of such securities may be required prior to maturity to execute management strategies. These securities are carried at fair value, with the unrealized gains and losses reported as a component of accumulated other comprehensive income (loss) in stockholders' equity until realized. Realized gains and losses from the sale of available-for-sale securities, if any, are determined on a specific identification basis. A decline in the market value of any available-for-sale security below cost that is determined to be other than temporary will result in an impairment charge to earnings and a new cost basis for the security is established. No such impairment charges were recorded for any period presented. It is not more likely than not that we will be required to sell investments before recovery of their amortized costs. Premiums and discounts are amortized or accreted over the life of the related security as an adjustment to yield using the straight-line method and included in interest income. Interest income is recognized when earned. Realized gains and losses on investments in securities are included in other income (expense) within the condensed consolidated statements of comprehensive income (loss).

Commitments_And_Contingencies_

Commitments And Contingencies Lease (Policies)	3 Months Ended
	Mar. 31, 2014
Leases [Abstract]	'
Leases	'
	We currently lease facilities and certain automotive equipment under non-cancelable operating leases expiring from April 1, 2014 through February 28, 2021. Rent expense is recognized on a straight-line basis over the initial lease term and those renewal periods that are reasonably assured as determined at lease inception. The difference between rent expense and rent paid is recorded as deferred rent and is included in other liabilities.

Schedule_of_Earnings_Per_Share

Schedule of Earnings Per Share, Basic and Diluted (Tables)	3 Months Ended
	Mar. 31, 2014
Earnings Per Share, Basic and Diluted [Abstract]	'
Schedule of Earnings Per Share, Basic and Diluted	'
	The following table sets forth the reconciliation of shares used to compute basic and diluted net loss per share for the periods indicated:
		Three Months Ended March 31,
	(shares in thousands)	2014	2013
	Weighted average shares outstanding - basic	18,518	19,322
	Dilutive potential common stock outstanding:
	Stock options	—	—
	Restricted stock units	—	—
	Weighted average shares outstanding - diluted	18,518	19,322
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	'
	The following weighted average outstanding common stock equivalents were not included in the calculation of diluted net loss per share because their effect was anti-dilutive:
		Three Months Ended March 31,
	(shares in thousands)	2014	2013
	Stock options	373	303
	Restricted stock units	—	16
	Total	373	319

Acquisition_of_Telerhythmics_T

Acquisition of Telerhythmics (Tables)	3 Months Ended
	Mar. 31, 2014
Business Combinations [Abstract]	'
Schedule of Purchase Price Allocation	'
		13-Mar-14
	Assets
	Current assets:
	Accounts receivable, net	$	200
	Other current assets	41
	Total current assets	241
	Property and equipment, net	290
	Intangible assets, net	2,580
	Goodwill	1,275
	Total assets	$	4,386
	Accounts payable	$	36
	Accrued compensation	169
	Other accrued liabilities	356
	Current portion of long-term debt	131
	Total current liabilities	692
	Other liabilities	174
	Total liabilities	$	866
Business Acquisition, Pro Forma Information	'
		Three Months Ended March 31, 2014							Three Months Ended March 31, 2013
		Digirad			Telerhythmics		Proforma		Digirad			Telerhythmics			Proforma
	Revenues	$	12,742		$	1,410	$	14,152	$	11,546		$	1,413		$	12,959
	Net income (loss)	$	19		$	7	$	26	$	(2,419	)	$	(115	)	$	(2,534	)
Schedule of Condensed Income Statement	'
		March 14, 2014 - March 31, 2014
	Revenues	$	255
	Net loss	$	(167	)

Inventories_Tables

Inventories (Tables)	3 Months Ended
	Mar. 31, 2014
Inventory Disclosure [Abstract]	'
Schedule of Inventory	'
	Our inventories are stated at the lower of cost (first-in, first-out) or market (net realizable value) and we review inventory balances for excess and obsolete inventory levels on a quarterly basis.
	(in thousands)	March 31,			December 31,
		2014			2013
	Raw materials	$	2,407		$	2,619
	Work-in-process	3,048			3,189
	Finished goods	669			616
		6,124			6,424
	Less reserve for excess and obsolete inventories	(2,369		)	(2,543		)
	Inventories, net	$	3,755		$	3,881

Property_and_Equipment_Tables

Property and Equipment (Tables)	3 Months Ended
	Mar. 31, 2014
Property and Equipment [Abstract]	'
Property and Equipment	'
	Property and Equipment
	(in thousands)	March 31,			December 31,
		2014			2013
	Machinery and equipment	$	23,216		$	22,596
	Computer hardware and software	2,520			2,497
	Leasehold improvements	900			861
		26,636			25,954
	Accumulated depreciation	(22,122		)	(21,801		)
	Property and equipment, net	$	4,514		$	4,153

Intangibles_and_Goodwill_Table

Intangibles and Goodwill (Tables)	3 Months Ended
	Mar. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Schedule of Intangible Assets and Goodwill	'
		31-Dec-13
		Weighted Average Useful Life (years)	Gross Carrying Amount		Accumulated Amortization			Intangible Assets, Net
	Intangible assets with infinite useful lives:
	Goodwill	Indefinite	$	184	$	—		$	184
	Intangible assets with finite useful lives:
	Customer relationships	3.5	$	2,940	$	(2,622	)	$	318
	Patents	4.9	141		(106		)	35
	Total intangible assets, net		$	3,081	$	(2,728	)	$	353
		31-Mar-14
		Weighted Average Useful Life (years)	Gross Carrying Amount		Accumulated Amortization			Intangible Assets, Net (1)
	Intangible assets with infinite useful lives:
	Goodwill (2)	Indefinite	$	1,459	$	—		$	1,459
	Intangible assets with finite useful lives:
	Customer relationships (2)	8.3	$	4,850	$	(2,682	)	$	2,168
	Trademarks (2)	9	600		(3		)	597
	Patents	4.8	141		(108		)	33
	Covenants not to compete (2)	5	70		(1		)	69
	Total intangible assets, net		$	5,661	$	(2,794	)	$	2,867

Restructuring_Charges_Tables

Restructuring Charges (Tables)	3 Months Ended
	Mar. 31, 2014
Restructuring and Related Activities [Abstract]	'
Schedule of Restructuring and Related Costs	'
	The following table includes information regarding our Facilities restructuring initiative:
	(in thousands)	Accrued at December 31, 2013		Accrued Costs		Cash Payments and Other Reductions		Accrued at March 31, 2014
	Total Facilities restructuring initiative	$	—	$	414	$	256	$	158
	The following table includes information regarding our Diagnostic Imaging restructuring initiative:
	(in thousands)	Accrued at December 31, 2013		Accrued Costs		Cash Payments and Other Reductions		Accrued at March 31, 2014
	Total Diagnostic Imaging restructuring initiative	$	489	$	27	$	396	$	120

Financial_Instruments_Tables

Financial Instruments (Tables)	3 Months Ended
	Mar. 31, 2014
Fair Value Disclosures [Abstract]	'
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques	'
	The following table presents information about our financial assets and liabilities that are measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation techniques we utilize to determine such fair value at March 31, 2014 and December 31, 2013.
		Fair Value as of March 31, 2014
	(in thousands)	Level 1				Level 2				Level 3				Total
	Assets:
	Corporate debt securities	$	—			$	9,871			$	—			$	9,871
	Liabilities:
	Acquisition related contingent consideration	$	—			$	—			$	220			$	220
		Fair Value as of December 31, 2013
	(in thousands)	Level 1				Level 2				Level 3				Total
	Assets:
	Corporate debt securities	$	—			$	7,673			$	—			$	7,673
Available-for-sale Securities	'
	The following table sets forth the composition of securities available-for-sale as of March 31, 2014 and December 31, 2013.
		Maturity in		Amortized Cost				Unrealized								Fair Value
	As of March 31, 2014 (in thousands)	Years						Gains				Losses
	Corporate debt securities	3 or less		$	9,891			$	6			$	(26	)		$	9,871
		Maturity in		Amortized Cost				Unrealized								Fair Value
	As of December 31, 2013 (in thousands)	Years						Gains				Losses
	Corporate debt securities	3 or less		$	7,675			$	—			$	(2	)		$	7,673

Commitments_And_Contingencies_1

Commitments And Contingencies Leases (Tables)	3 Months Ended
	Mar. 31, 2014
Leases [Abstract]	'
Schedule of Property Subject to or Available for Operating Lease	'
		Operating		Capital
		Leases		Leases
	2014	$	662	$	161
	2015	883		214
	2016	522		140
	2017	258		24
	2018	215		3
	2019	221		—
	Thereafter	266		—
	Total minimum lease payments	$	3,027	$	542

Segments_Tables

Segments (Tables)	3 Months Ended
	Mar. 31, 2014
Segment Reporting [Abstract]	'
Schedule of Segment Reporting Information, by Segment	'
	Our reportable segments have been determined based on the nature of the products and/or services offered to customers or the nature of their function in the organization. We evaluate performance based on the operating income (loss) contributed by each segment.
	On March 13, 2014, we acquired all the outstanding membership interest of Telerhythmics, LLC (See Note 3). As part of the acquisition, we evaluated Telerhythmics' business operations, both on a quantitative and qualitative basis, and determined its business operations appropriately met the criteria to be aggregated with our Diagnostic Services business in accordance with the authoritative accounting guidance for segment reporting. The Diagnostic Services reportable segment was renamed in conjunction with the acquisition from Digirad Imaging Solutions.
	The financial results below for the three months ended March 31, 2014 include the financial results of Telerhythmics, LLC for the period since the acquisition date of March 13, 2014.
		Three Months Ended March 31,
	(in thousands)	2014			2013
	Gross profit by segment:
	Diagnostic Services	$	2,021		$	2,114
	Diagnostic Imaging	1,421			703
	Condensed consolidated gross profit	$	3,442		$	2,817
	Income (loss) from operations by segment:
	Diagnostic Services	$	(333	)	$	(144	)
	Diagnostic Imaging (1)	178			(2,265		)
	Condensed consolidated loss from operations	$	(155	)	$	(2,409	)
	Depreciation and amortization:
	Diagnostic Services	$	375		$	392
	Diagnostic Imaging	78			101
	Condensed consolidated depreciation and amortization	$	453		$	493
Reconciliation of Assets from Segment to Consolidated	'
	(in thousands)	As of March 31, 2014			As of December 31, 2013
	Identifiable assets by segment:
	Diagnostic Services	$	15,172		$	11,874
	Diagnostic Imaging	25,387			29,577
	Condensed Consolidated assets	$	40,559		$	41,451
	(1) Included in the Diagnostic Imaging income (loss) from operations for the three months ended March 31, 2014 and 2013, are approximately $0.4 million and $1.0 million of charges, respectively, associated with our Diagnostic Imaging restructuring initiative (See Note 7)

The_Company_Details

The Company (Details)	3 Months Ended
	Mar. 31, 2014
	segment
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Number of reportable segments	2

Basic_and_Diluted_Net_Income_p

Basic and Diluted Net Income per Share (Details)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Earnings Per Share, Basic and Diluted [Abstract]	'	'
Weighted average shares outstanding – basic	18,518	19,322
Dilutive potential common stock outstanding:	'	'
Stock options	0	0
Restricted stock units	0	0
Weighted average shares outstanding – diluted	18,518	19,322
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	373	319
Stock Options [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	373	303
Restricted Stock Units (RSUs) [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0	16

Acquisition_of_Telerhythmics_D

Acquisition of Telerhythmics (Details) (USD $)	1 Months Ended	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2014	Mar. 31, 2013	Mar. 13, 2014
Business Acquisition, Contingent Consideration [Line Items]	'	'	'	'
Business Acquisition, Expected Working Capital Adjustment	'	'	'	$49,000
Business Acquisition, Percentage of Voting Interests Acquired	'	'	'	100.00%
Business Acquisition, Cost of Acquired Entity, Cash Paid	3,520,000	3,520,000	'	'
Business Acquisition, Contingent Consideration, Potential Cash Payment	220,000	220,000	'	501,000
Percentage Of EBITDA To Be Received	50.00%	'	'	'
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months	400,000	400,000	'	'
Accounts receivable, net	'	'	'	200,000
Other current assets	'	'	'	41,000
Total current assets	'	'	'	241,000
Property and equipment, net	'	'	'	290,000
Intangible assets, net	'	'	'	2,580,000
Goodwill	'	'	'	1,275,000
Total assets	'	'	'	4,386,000
Accounts payable	'	'	'	36,000
Current portion of long-term debt	'	'	'	131,000
Total current liabilities	'	'	'	692,000
Other liabilities	'	'	'	174,000
Total liabilities	'	'	'	866,000
Gross Profit	'	3,442,000	2,817,000	'
Operating Expenses	'	3,597,000	5,226,000	'
Income Tax Expense (Benefit)	'	2,000	32,000	'
Revenues	'	14,152,000	12,959,000	'
Net income (loss)	'	26,000	-2,534,000	'
Revenues	255,000	'	'	'
Net loss	-167,000	-148,000	-2,419,000	'
Business Acquisition, Cost of Acquired Entity, Transaction Costs	155,000	155,000	'	'
Year one [Member]	'	'	'	'
Business Acquisition, Contingent Consideration [Line Items]	'	'	'	'
Business Acquisition, Contingent Consideration, Potential Cash Payment	'	'	'	415,000
Year two [Member]	'	'	'	'
Business Acquisition, Contingent Consideration [Line Items]	'	'	'	'
Business Acquisition, Contingent Consideration, Potential Cash Payment	'	'	'	825,000
Year three [Member]	'	'	'	'
Business Acquisition, Contingent Consideration [Line Items]	'	'	'	'
Business Acquisition, Contingent Consideration, Potential Cash Payment	'	'	'	825,000
accrued compensation [Member]	'	'	'	'
Business Acquisition, Contingent Consideration [Line Items]	'	'	'	'
Business Acquisition, Purchase Price Allocation, Current Liabilities, Accrued Liabilities	'	'	'	169,000
other accrued liabilities [Member]	'	'	'	'
Business Acquisition, Contingent Consideration [Line Items]	'	'	'	'
Business Acquisition, Purchase Price Allocation, Current Liabilities, Accrued Liabilities	'	'	'	356,000
Telerhythmics [Member]	'	'	'	'
Business Acquisition, Contingent Consideration [Line Items]	'	'	'	'
Revenues	'	1,410,000	1,413,000	'
Net income (loss)	'	7,000	-115,000	'
digirad [Member]	'	'	'	'
Business Acquisition, Contingent Consideration [Line Items]	'	'	'	'
Revenues	'	12,742,000	11,546,000	'
Net income (loss)	'	$19,000	($2,419,000)	'

Inventories_Details

Inventories (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Inventory Disclosure [Abstract]	'	'
Raw materials	$2,407	$2,619
Work-in-process	3,048	3,189
Finished goods	669	616
Inventory, gross	6,124	6,424
Less reserve for excess and obsolete inventories	-2,369	-2,543
Inventories, net	$3,755	$3,881

Property_and_Equipment_Details

Property and Equipment (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Property, Plant and Equipment [Line Items]	'	'
Property, and equipment, gross	$26,636	$25,954
Accumulated depreciation	-22,122	-21,801
Property and equipment, net	4,514	4,153
Machinery and equipment	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, and equipment, gross	23,216	22,596
Computer hardware and software	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, and equipment, gross	2,520	2,497
Leasehold improvements	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, and equipment, gross	$900	$861

Intangibles_and_Goodwill_Detai

Intangibles and Goodwill (Details) (USD $)	3 Months Ended			3 Months Ended	12 Months Ended	3 Months Ended		12 Months Ended	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2014	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2014
				Customer Relationships [Member]	Customer Relationships [Member]	Trademarks [Member]	Patents [Member]	Patents [Member]	Noncompete Agreements [Member]
Finite-Lived Intangible Assets [Line Items]	'	'	'	'	'	'	'	'	'
Goodwill, Gross	$1,459,000	'	$184,000	'	'	'	'	'	'
Goodwill	1,459,000	'	184,000	'	'	'	'	'	'
Finite-Lived Intangible Asset, Useful Life	'	'	'	'8 years 3 months 18 days	'3 years 6 months	'8 years 11 months 15 days	'4 years 9 months 18 days	'4 years 10 months 24 days	'4 years 11 months 15 days
Finite-Lived Intangible Assets, Gross	5,661,000	'	3,081,000	4,850,000	2,940,000	600,000	141,000	141,000	70,000
Finite-Lived Intangible Assets, Accumulated Amortization	-2,794,000	'	-2,728,000	-2,682,000	-2,622,000	-3,000	-108,000	-106,000	-1,000
Finite-Lived Intangible Assets, Net	2,867,000	'	353,000	2,168,000	318,000	597,000	33,000	35,000	69,000
Amortization of intangible assets	66,000	66,000	'	'	'	'	'	'	'
2014	300,000	'	'	'	'	'	'	'	'
2015	400,000	'	'	'	'	'	'	'	'
2016	400,000	'	'	'	'	'	'	'	'
2017	400,000	'	'	'	'	'	'	'	'
2018	300,000	'	'	'	'	'	'	'	'
Thereafter	$1,200,000	'	'	'	'	'	'	'	'

Restructuring_Charges_Narrativ

Restructuring Charges - Narrative (Details) (USD $)	3 Months Ended			15 Months Ended		3 Months Ended			3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2014	Mar. 31, 2014	Mar. 31, 2014	Jan. 24, 2014	Jan. 23, 2014	Mar. 31, 2014	Mar. 31, 2014
			Diagnostic Imaging Initiative [Member]	Diagnostic Imaging Initiative [Member]	Diagnostic Imaging Initiative [Member]	Facilities Restructuring Initiative [Member]	Facilities Restructuring Initiative [Member]	Facilities Restructuring Initiative [Member]	Facilities Restructuring Initiative [Member]	Facilities Restructuring Initiative [Member]
					Employee Severance [Member]		sqft	sqft	Minimum [Member]	Maximum [Member]
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'	'	'	'	'
Area of Real Estate Property	'	'	'	'	'	'	47,000	21,300	'	'
Restructuring and Related Cost, Expected Cost	'	'	'	'	'	'	'	'	$500,000	$700,000
Estimated employee related restructuring charges	'	'	'	1,800,000	1,600,000	400,000	'	'	'	'
Restructuring charges	$441,000	$1,004,000	$27,000	'	'	$414,000	'	'	'	'

Restructuring_Charges_Diagnost

Restructuring Charges - Diagnostic Imaging Restructuring Initiative (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Restructuring Reserve [Roll Forward]	'	'
Accrued Costs	$441	$1,004
Diagnostic Imaging Initiative [Member]	'	'
Restructuring Reserve [Roll Forward]	'	'
Accrued at December 31, 2013	489	'
Accrued Costs	27	'
Cash Payments and Other Reductions	396	'
Accrued at March 31, 2014	$120	'

Restructuring_Charges_Faciliti

Restructuring Charges - Facilities restructuring initiative (Details) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Restructuring Cost and Reserve [Line Items]	'	'
Restructuring charges	$441,000	$1,004,000
Facilities Restructuring Initiative [Member]	'	'
Restructuring Cost and Reserve [Line Items]	'	'
Accrued at December 31, 2013	0	'
Restructuring and Related Cost, Incurred Cost	400,000	'
Restructuring charges	414,000	'
Cash Payments and Other Reductions	256,000	'
Accrued at March 31, 2014	$158,000	'

Financial_Instruments_Assets_a

Financial Instruments Assets and Liabilities at Fair Value on a Recurring Basis (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Level 1	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Acquisition related contingent consideration	$0	'
Level 1 | Corporate debt securities	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Corporate debt securities	0	0
Level 2	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Acquisition related contingent consideration	0	'
Level 2 | Corporate debt securities	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Corporate debt securities	9,871	7,673
Level 3	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Acquisition related contingent consideration	220	'
Level 3 | Corporate debt securities	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Corporate debt securities	0	0
Total	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Acquisition related contingent consideration	220	'
Total | Corporate debt securities	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Corporate debt securities	$9,871	$7,673

Financial_Instruments_Securiti

Financial Instruments Securities Available for Sale (Details) (3 or less, Corporate debt securities, USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
3 or less | Corporate debt securities	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Maturities in Years	'3 years	'3 years
Amortized Cost	$9,891	$7,675
Unrealized Gains	6	0
Unrealized Losses	-26	-2
Fair Value	$9,871	$7,673

Recovered_Sheet1

Commitments and Contingencies (Details) (USD $)	3 Months Ended
	Mar. 31, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Rent expense	$400,000
2014	662,000
2015	883,000
2016	522,000
2017	258,000
2018	215,000
2019	221,000
Thereafter	266,000
Total minimum lease payments	3,027,000
2014	161,000
2015	214,000
2016	140,000
2017	24,000
2018	3,000
2019	0
Thereafter	0
Total minimum lease payments	$542,000

Income_Tax_Details

Income Tax (Details) (USD $)	Dec. 31, 2013
In Millions, unless otherwise specified
Income Tax Disclosure [Abstract]	'
Unrecognized tax benefits	$1.60
Unrecognized tax benefits that would impact effective tax rate	$1.30

Segments_Details

Segments (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014		Mar. 31, 2013
Segment Reporting Information [Line Items]	'		'
Gross profit by segment:	$3,442		$2,817
Income (loss) from operations by segment:	-155		-2,409
Depreciation and amortization:	453		493
DIS [Member]	'		'
Segment Reporting Information [Line Items]	'		'
Gross profit by segment:	2,021		2,114
Income (loss) from operations by segment:	-333		-144
Depreciation and amortization:	375		392
Diagnostic Imaging [Member]	'		'
Segment Reporting Information [Line Items]	'		'
Gross profit by segment:	1,421		703
Income (loss) from operations by segment:	178	[1]	-2,265
Depreciation and amortization:	$78		$101
[1]	Included in the Diagnostic Imaging income (loss) from operations for the three months ended March 31, 2014 and 2013, are approximately $0.4 million and $1.0 million of charges, respectively, associated with our Diagnostic Imaging restructuring initiative (See Note 7)

Segments_Asset_by_Segment_Deta

Segments Asset by Segment Detail (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013
Segment Reporting Information [Line Items]	'	'	'
Identifiable assets by segment	$40,559	'	$41,451
Restructuring charges	441	1,004	'
Diagnostic Services	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Identifiable assets by segment	15,172	'	11,874
Diagnostic Imaging	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Identifiable assets by segment	$25,387	'	$29,577

Subsequent_Event_Dividend_Deta

Subsequent Event Dividend (Details) (USD $)	3 Months Ended		0 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	1-May-14
			Subsequent event
Subsequent Event [Line Items]	'	'	'
Dividends declared per common share	$0.05	$0	$0.05